ANTI-VLA-4 Related Assays
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/US2010/052172, filed Oct 11, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,377,458 | ANTI-VLA-4 Related Assays In force · High confidence | Biogen Ma Inc. | In force | High confidence | ||
| US 9,726,672 | ANTI-VLA-4 Related Assays In force · Medium confidence | Biogen Ma Inc. | In force | Medium confidence | ||
| US 10,302,654 | ANTI-VLA-4 Related Assays In force · Medium confidence | Biogen Ma Inc. | In force | Medium confidence | ||
| US 12,385,925 | ANTI-VLA-4 Related Assays In force · High confidence | Biogen Ma Inc. | In force | High confidence | ||
| US 11,280,793 | ANTI-VLA-4 Related Assays In force · High confidence | Biogen Ma Inc. | In force | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.